Cargando…

Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism

BACKGROUND: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). The inflammatory response plays a critical role in DN. ZiShenWan (ZSW) is a classical Chinese medicinal formula with remarkable clinical therapeutic effects on DN, but its pharmacological action mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiaoyuan, Wu, You, Zhang, Chengfei, Wu, Lili, Qin, Lingling, Liu, Tonghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055297/
https://www.ncbi.nlm.nih.gov/pubmed/33883881
http://dx.doi.org/10.2147/DDDT.S297683
_version_ 1783680425593405440
author Guo, Xiaoyuan
Wu, You
Zhang, Chengfei
Wu, Lili
Qin, Lingling
Liu, Tonghua
author_facet Guo, Xiaoyuan
Wu, You
Zhang, Chengfei
Wu, Lili
Qin, Lingling
Liu, Tonghua
author_sort Guo, Xiaoyuan
collection PubMed
description BACKGROUND: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). The inflammatory response plays a critical role in DN. ZiShenWan (ZSW) is a classical Chinese medicinal formula with remarkable clinical therapeutic effects on DN, but its pharmacological action mechanisms remain unclear. AIM: In this study, a network pharmacology approach was applied to investigate the pharmacological mechanisms of ZSW in DN therapy. Based on the results of network analysis, the core targets and signaling pathways related to anti-inflammatory effect were verified via experiments in vivo. METHODS: The candidate chemical ingredients of ZSW as well as its putative targets and known therapeutic targets of DN were acquired from appropriate databases. The “herb-ingredient-target” network for ZSW in DN treatment was established. The protein–protein interaction (PPI) network of potential targets was constructed to screen the core targets. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. In addition to biochemical and pathological indicators, the core targets and signaling pathways associated with inflammation were partially validated in db/db mice at molecular level. RESULTS: A total of 56 active ingredients in ZSW and 166 DN-related targets were selected from databases. A high proportion of core targets and top signaling pathways participate in inflammation. ZSW markedly alleviated renal injuries pathologically and regulated related biomarkers. In particular, ZSW significantly inhibited the exaggerated release of inflammatory cytokines such as interleukin (IL)-1β, IL-6, tumor necrosis factor receptor (TNF)-ɑ, and monocyte chemotactic protein (MCP)-1 as well as regulating p38 mitogen-activated protein kinases (MAPK) and phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt) signaling pathways in db/db mice. CONCLUSION: This study first comprehensively investigated the active ingredients, potential targets, and molecular mechanism of ZSW as a therapy for DN. ZSW achieved renoprotective effects in DN via regulation of multiple targets and signaling pathways, especially by alleviating inflammation. Results indicate that ZSW is a promising multi-target therapeutic approach for DN treatment.
format Online
Article
Text
id pubmed-8055297
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80552972021-04-20 Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism Guo, Xiaoyuan Wu, You Zhang, Chengfei Wu, Lili Qin, Lingling Liu, Tonghua Drug Des Devel Ther Original Research BACKGROUND: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). The inflammatory response plays a critical role in DN. ZiShenWan (ZSW) is a classical Chinese medicinal formula with remarkable clinical therapeutic effects on DN, but its pharmacological action mechanisms remain unclear. AIM: In this study, a network pharmacology approach was applied to investigate the pharmacological mechanisms of ZSW in DN therapy. Based on the results of network analysis, the core targets and signaling pathways related to anti-inflammatory effect were verified via experiments in vivo. METHODS: The candidate chemical ingredients of ZSW as well as its putative targets and known therapeutic targets of DN were acquired from appropriate databases. The “herb-ingredient-target” network for ZSW in DN treatment was established. The protein–protein interaction (PPI) network of potential targets was constructed to screen the core targets. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. In addition to biochemical and pathological indicators, the core targets and signaling pathways associated with inflammation were partially validated in db/db mice at molecular level. RESULTS: A total of 56 active ingredients in ZSW and 166 DN-related targets were selected from databases. A high proportion of core targets and top signaling pathways participate in inflammation. ZSW markedly alleviated renal injuries pathologically and regulated related biomarkers. In particular, ZSW significantly inhibited the exaggerated release of inflammatory cytokines such as interleukin (IL)-1β, IL-6, tumor necrosis factor receptor (TNF)-ɑ, and monocyte chemotactic protein (MCP)-1 as well as regulating p38 mitogen-activated protein kinases (MAPK) and phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt) signaling pathways in db/db mice. CONCLUSION: This study first comprehensively investigated the active ingredients, potential targets, and molecular mechanism of ZSW as a therapy for DN. ZSW achieved renoprotective effects in DN via regulation of multiple targets and signaling pathways, especially by alleviating inflammation. Results indicate that ZSW is a promising multi-target therapeutic approach for DN treatment. Dove 2021-04-15 /pmc/articles/PMC8055297/ /pubmed/33883881 http://dx.doi.org/10.2147/DDDT.S297683 Text en © 2021 Guo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Guo, Xiaoyuan
Wu, You
Zhang, Chengfei
Wu, Lili
Qin, Lingling
Liu, Tonghua
Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism
title Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism
title_full Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism
title_fullStr Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism
title_full_unstemmed Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism
title_short Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism
title_sort network pharmacology analysis of zishenwan for diabetic nephropathy and experimental verification of its anti-inflammatory mechanism
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055297/
https://www.ncbi.nlm.nih.gov/pubmed/33883881
http://dx.doi.org/10.2147/DDDT.S297683
work_keys_str_mv AT guoxiaoyuan networkpharmacologyanalysisofzishenwanfordiabeticnephropathyandexperimentalverificationofitsantiinflammatorymechanism
AT wuyou networkpharmacologyanalysisofzishenwanfordiabeticnephropathyandexperimentalverificationofitsantiinflammatorymechanism
AT zhangchengfei networkpharmacologyanalysisofzishenwanfordiabeticnephropathyandexperimentalverificationofitsantiinflammatorymechanism
AT wulili networkpharmacologyanalysisofzishenwanfordiabeticnephropathyandexperimentalverificationofitsantiinflammatorymechanism
AT qinlingling networkpharmacologyanalysisofzishenwanfordiabeticnephropathyandexperimentalverificationofitsantiinflammatorymechanism
AT liutonghua networkpharmacologyanalysisofzishenwanfordiabeticnephropathyandexperimentalverificationofitsantiinflammatorymechanism